CA2984422C - Preparations d'anticorps anti-interleukines a administrer dans la lumiere du tractus intestinal au moyen d'un dispositif d'administration pharmacologique a avaler - Google Patents

Preparations d'anticorps anti-interleukines a administrer dans la lumiere du tractus intestinal au moyen d'un dispositif d'administration pharmacologique a avaler Download PDF

Info

Publication number
CA2984422C
CA2984422C CA2984422A CA2984422A CA2984422C CA 2984422 C CA2984422 C CA 2984422C CA 2984422 A CA2984422 A CA 2984422A CA 2984422 A CA2984422 A CA 2984422A CA 2984422 C CA2984422 C CA 2984422C
Authority
CA
Canada
Prior art keywords
antibody
preparation
intestinal wall
capsule
tissue penetrating
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
CA2984422A
Other languages
English (en)
Other versions
CA2984422A1 (fr
Inventor
Mir Imran
Radhika KORUPOLU
Elaine TO
Mir Hashim
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Rani Therapeutics LLC
Original Assignee
Rani Therapeutics LLC
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Rani Therapeutics LLC filed Critical Rani Therapeutics LLC
Publication of CA2984422A1 publication Critical patent/CA2984422A1/fr
Application granted granted Critical
Publication of CA2984422C publication Critical patent/CA2984422C/fr
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4808—Preparations in capsules, e.g. of gelatin, of chocolate characterised by the form of the capsule or the structure of the filling; Capsules containing small tablets; Capsules with outer layer for immediate drug release
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4841—Filling excipients; Inactive ingredients
    • A61K9/4866—Organic macromolecular compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
    • A61M31/00—Devices for introducing or retaining media, e.g. remedies, in cavities of the body
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/24—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
    • C07K16/244—Interleukins [IL]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2866—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for cytokines, lymphokines, interferons
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/40—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against enzymes
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • Epidemiology (AREA)
  • Hematology (AREA)
  • Rheumatology (AREA)
  • Microbiology (AREA)
  • Anesthesiology (AREA)
  • Dermatology (AREA)
  • Pain & Pain Management (AREA)
  • Mycology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Diabetes (AREA)
  • Biomedical Technology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Medicinal Preparation (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medical Preparation Storing Or Oral Administration Devices (AREA)
  • Materials For Medical Uses (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

L'invention concerne, dans certains modes de réalisation, des dispositifs à avaler, des préparations et des procédés permettant d'administrer des agents thérapeutiques dans le tractus gastro-intestinal tels que des protéines neutralisantes, en particulier des anticorps qui neutralisent des interleukines. De nombreux modes de réalisation portent sur un dispositif à avaler, par exemple une capsule, pour administrer divers agents dans la paroi intestinale. Certains modes de réalisation concernent aussi des préparations d'agent conçues pour être contenues dans la capsule, la capsule traversant la paroi intestinale, se dégradant puis libérant l'agent dans le sang pour produire un effet thérapeutique. La préparation peut être couplée de manière fonctionnelle à des moyens d'administration qui ont une première configuration où la préparation est contenue dans la capsule, et une seconde configuration où la préparation traverse la paroi intestinale hors de la capsule. Les modes de réalisation de l'invention sont particulièrement utiles pour administrer des protéines neutralisant les interleukines dans le cadre du traitement de maladies inflammatoires où ces protéines qui neutralisent les interleukines sont mal absorbées, mal tolérées et/ou sont dégradées dans le tractus gastro-intestinal.
CA2984422A 2015-05-08 2016-05-09 Preparations d'anticorps anti-interleukines a administrer dans la lumiere du tractus intestinal au moyen d'un dispositif d'administration pharmacologique a avaler Active CA2984422C (fr)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201562159134P 2015-05-08 2015-05-08
US62/159,134 2015-05-08
PCT/US2016/031548 WO2016183040A1 (fr) 2015-05-08 2016-05-09 Préparations d'anticorps anti-interleukines à administrer dans la lumière du tractus intestinal au moyen d'un dispositif d'administration pharmacologique à avaler

Publications (2)

Publication Number Publication Date
CA2984422A1 CA2984422A1 (fr) 2016-11-17
CA2984422C true CA2984422C (fr) 2023-10-17

Family

ID=57248408

Family Applications (1)

Application Number Title Priority Date Filing Date
CA2984422A Active CA2984422C (fr) 2015-05-08 2016-05-09 Preparations d'anticorps anti-interleukines a administrer dans la lumiere du tractus intestinal au moyen d'un dispositif d'administration pharmacologique a avaler

Country Status (6)

Country Link
EP (1) EP3294273A4 (fr)
JP (2) JP7185401B2 (fr)
CN (1) CN107835682A (fr)
AU (2) AU2016261599B2 (fr)
CA (1) CA2984422C (fr)
WO (1) WO2016183040A1 (fr)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US11548940B2 (en) 2014-05-15 2023-01-10 Rani Therapeutics, Llc Anti-interleukin antibody preparations for delivery into a lumen of the intestinal tract using a swallowable drug delivery device
US10689460B2 (en) 2014-05-15 2020-06-23 Incube Labs, Llc PCSK9 antibody preparations for delivery into a lumen of the intestinal tract using a swallowable drug delivery device
CN108401419A (zh) * 2015-09-08 2018-08-14 因库博实验室有限责任公司 使用可吞服药物递送装置递送到肠道内腔中的pcsk9抗体制剂
WO2018112256A1 (fr) * 2016-12-14 2018-06-21 Progenity Inc. Traitement d'une maladie du tractus gastro-intestinal avec un inhibiteur d'il-1
WO2020142538A1 (fr) * 2018-12-31 2020-07-09 Incube Labs, Llc Préparations d'agent thérapeutique à administrer dans une lumière du tractus intestinal au moyen d'un dispositif d'administration de médicament à avaler

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS6024767B2 (ja) * 1979-08-24 1985-06-14 塩野義製薬株式会社 腸溶性硬カプセル剤
WO2006052660A2 (fr) * 2004-11-04 2006-05-18 Childrens Hospital Los Angeles Research Institute Blocage du recepteur il-7 pour supprimer l'immunite
MX2009002756A (es) * 2006-09-12 2009-05-25 Cosmo Technologies Ltd Composiciones farmaceuticas para la administracion oral o rectal de sustancias proteinicas.
GB0722484D0 (en) * 2007-11-15 2007-12-27 Ucl Business Plc Solid compositions
US8562589B2 (en) * 2009-12-24 2013-10-22 Rani Therapeutics, Llc Swallowable drug delivery device and method of delivery
EP2515992B1 (fr) 2009-12-24 2018-10-10 Rani Therapeutics, LLC Dispositif d'administration de médicament avalable
US8524215B2 (en) * 2010-08-02 2013-09-03 Janssen Biotech, Inc. Absorbable PEG-based hydrogels
US9149617B2 (en) * 2010-12-23 2015-10-06 Rani Therapeutics, Llc Device, system and methods for the oral delivery of therapeutic compounds
US8980822B2 (en) * 2010-12-23 2015-03-17 Rani Therapeutics, Llc Therapeutic agent preparations comprising pramlintide for delivery into a lumen of the intestinal tract using a swallowable drug delivery device
EP3653224A1 (fr) 2011-06-29 2020-05-20 Rani Therapeutics, LLC Préparations d'agent thérapeutique pour l'administration dans une lumière du tractus intestinal à l'aide d'un dispositif d'administration de médicaments à avaler
PL3653223T3 (pl) 2011-06-29 2021-12-20 Rani Therapeutics, Llc Urządzenie do doustnego dostarczania związków leczniczych
BR112015008186A2 (pt) * 2012-10-25 2017-09-19 Medimmune Llc formulação de um anticorpo estável e de baixa viscosidade
US20150064241A1 (en) * 2013-09-05 2015-03-05 Google Inc. Delivery of Functionalized Particles
AU2015258859B2 (en) * 2014-05-15 2020-07-23 Rani Therapeutics, Llc Pharmaceutical compositions and methods for fabrication of solid masses comprising polypeptides and/or proteins
EP3288543A4 (fr) * 2015-05-01 2018-11-14 Incube Labs, LLC Compositions pharmaceutiques et procédés de fabrication de masses solides comprenant des polypeptides et/ou des protéines

Also Published As

Publication number Publication date
AU2016261599A1 (en) 2017-11-23
EP3294273A4 (fr) 2018-12-05
JP2018520995A (ja) 2018-08-02
CA2984422A1 (fr) 2016-11-17
JP7232805B2 (ja) 2023-03-03
AU2016261599B2 (en) 2021-08-26
JP2021042239A (ja) 2021-03-18
JP7185401B2 (ja) 2022-12-07
AU2021269453A1 (en) 2021-12-16
WO2016183040A1 (fr) 2016-11-17
CN107835682A (zh) 2018-03-23
EP3294273A1 (fr) 2018-03-21

Similar Documents

Publication Publication Date Title
US20230174639A1 (en) Anti-interleukin antibody preparations for delivery into a lumen of the intestinal tract using a swallowable drug delivery device
US11814427B2 (en) Therapeutic agent preparations for delivery into a lumen of the intestinal tract using a swallowable drug delivery device
US10300010B2 (en) Methods for delivering entanercept preparations into a lumen of the intestinal tract using a swallowable drug delivery device
US11419812B2 (en) Methods for delivering etanercept preparations into a lumen of the intestinal tract using a swallowable drug delivery device
CA2840617C (fr) Preparations d'agent therapeutique a administrer dans une lumiere du tractus intestinal au moyen d'un dispositif d'administration de medicament avalable
US10689460B2 (en) PCSK9 antibody preparations for delivery into a lumen of the intestinal tract using a swallowable drug delivery device
US20170081399A1 (en) Therapeutic agent preparations for delivery into a lumen of the intestinal tract using a swallowable drug delivery device
AU2021269453A1 (en) Anti-interleukin antibody preparations for delivery into a lumen of the intestinal tract using a swallowable drug delivery device
AU2023204153A1 (en) PCSK9 antibody preparations for delivery into a lumen of the intestinal tract using a swallowable drug delivery device
US12018090B2 (en) PCSK9 antibody preparations for delivery into a lumen of the intestinal tract using a swallowable drug delivery device
US20230374155A1 (en) Pcsk9 antibody preparations for delivery into a lumen of the intestinal tract using a swallowable drug delivery device

Legal Events

Date Code Title Description
EEER Examination request

Effective date: 20210429

EEER Examination request

Effective date: 20210429

EEER Examination request

Effective date: 20210429

EEER Examination request

Effective date: 20210429

EEER Examination request

Effective date: 20210429

EEER Examination request

Effective date: 20210429

EEER Examination request

Effective date: 20210429

EEER Examination request

Effective date: 20210429

EEER Examination request

Effective date: 20210429